Alicia de las Heras, M.D., is a hematologist and member of the Clinical Investigator team at the Early Phase Clinical Trials Unit at START Madrid-FJD. She completed her medical studies at Universidad Autónoma de Madrid from 2015 to 2020 and her specialist training in Hematology and Hemotherapy at Hospital Universitario Fundación Jiménez Díaz from 2021 to 2025.

In 2025, she completed a two-month observership at Dana-Farber Cancer Institute in Boston, focusing on outpatient hematology and clinical trials. She has also received multidisciplinary training in clinical research, including participation in the Methods in Clinical Cancer Research (MCCR) program.

She joined START Madrid-FJD as a Clinical Fellow in July 2025 and became part of its Clinical Investigator team in 2026. She also works as a hematologist in the Multiple Myeloma Unit at Hospital Universitario Fundación Jiménez Díaz, where she is involved in phase III clinical trials. Her main interests include hematologic malignancies, particularly multiple myeloma, early-phase drug development, and innovative therapies.